De­spite tri­al dis­con­tin­u­a­tions, Rhythm’s ge­net­ic obe­si­ty drug ef­fec­tive in an­oth­er rare in­di­ca­tion 

Fol­low­ing a sec­ond FDA OK for its ge­net­ic obe­si­ty drug last month for pa­tients with Bardet-Biedl syn­drome, Rhythm Phar­ma­ceu­ti­cals con­tin­ues its quest to ex­pand the in­di­ca­tion for its drug Im­civree.

The Boston-based biotech dropped in­ter­im Phase II da­ta for hy­po­thal­a­m­ic obe­si­ty show­ing that 11 of 11 pa­tients who com­plet­ed treat­ment met the pri­ma­ry end­point of a 5% de­crease in BMI at 16 weeks. Most pa­tients sur­passed the end­point, as on av­er­age, the pa­tients saw a 17% re­duc­tion in BMI.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER